APA (7th ed.) Citation

Wang, W., Wang, M., Li, Z., Huang, X., Wang, S., Jin, C., . . . Shen, Y. (2023). 678 Updated safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): A phase Ib/II clinical trial. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Wang, Wei, et al. 678 Updated Safety and Efficacy of Toripalimab Combined with Cetuximab in Platinum-refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M-HNSCC): A Phase Ib/II Clinical Trial. BMJ Publishing Group, 2023.

MLA (9th ed.) Citation

Wang, Wei, et al. 678 Updated Safety and Efficacy of Toripalimab Combined with Cetuximab in Platinum-refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M-HNSCC): A Phase Ib/II Clinical Trial. BMJ Publishing Group, 2023.